Freja Bach Kampmann

Discussion The Inter99 cohort has contributed substantially to our understanding of the multifactorial origin, natural history, as well as potential for early detection and prevention of T2D and its associated cardiometabolic co-morbidities. While it, from a modern epidemiological perspective may appear relatively small, the Inter99 cohort is firmly established as an international competitive cardiometabolic epidemiological research resource due to its high data quality and data richness.

Methods and analyses Trial design and setting The InterVitaminK trial is a population-based, double-blinded, placebo-controlled, randomised intervention trial (figure 1). The InterVitaminK trial will be carried out at the Centre for Clinical Research and Prevention, Denmark. The cardiac CT scans will be performed at the department of cardiology, Rigshospitalet, Copenhagen, Denmark.